Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carenoprazan vs esomeprazole in bismuth quadruple therapy for Helicobacter pylori eradication
CTR20220508Phase 3Completed
- Sponsor
- Nanjing Kefepin Shenghui Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of keverprazan in Helicobacter pylori infection, sponsored by Nanjing Kefepin Shenghui Pharmaceutical. Started Mar 2022; status: completed.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20220508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220508.